TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,495,937 | +83.4% | 1,276,878 | +100.6% | 0.10% | +61.3% |
| Q4 2023 | $5,723,223 | -70.2% | 636,621 | -70.4% | 0.06% | -72.4% |
| Q3 2023 | $19,226,051 | +20.3% | 2,150,565 | +106.7% | 0.22% | +19.0% |
| Q2 2023 | $15,978,947 | -50.7% | 1,040,296 | -27.7% | 0.19% | -57.1% |
| Q1 2023 | $32,378,831 | +1488.8% | 1,439,699 | +1385.6% | 0.44% | +1533.3% |
| Q4 2022 | $2,037,975 | -69.2% | 96,908 | -63.9% | 0.03% | -70.7% |
| Q3 2022 | $6,608,000 | +86.7% | 268,175 | +83.8% | 0.09% | +58.6% |
| Q3 2021 | $3,539,000 | – | 145,918 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,776,728 | $14,604,704 | 4.15% |
| Exome Asset Management LLC | 443,379 | $3,644,576 | 3.17% |
| Deep Track Capital, LP | 7,370,000 | $60,581,400 | 1.81% |
| Talbot Financial, LLC | 63,546 | $12,921,444 | 1.67% |
| Kynam Capital Management, LP | 2,021,659 | $16,618,037 | 1.28% |
| Rock Springs Capital Management LP | 4,482,265 | $36,844,218 | 1.11% |
| Parkman Healthcare Partners LLC | 969,892 | $7,972,512 | 1.07% |
| Birchview Capital, LP | 122,000 | $1,002,840 | 0.93% |
| Knott David M Jr | 265,966 | $2,186 | 0.87% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $61,650,000 | 0.78% |